| Revision as of 22:42, 13 November 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (changes to verified fields - updated 'ChemSpiderID_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProject_...← Previous edit |
Latest revision as of 20:54, 1 December 2023 edit undoBuidhe (talk | contribs)Autopatrolled, Extended confirmed users, Page movers, File movers, Mass message senders, New page reviewers, Pending changes reviewers, Template editors136,149 editsm Moving from Category:Experimental drugs to Category:Experimental antiviral drugs using Cat-a-lot |
| (9 intermediate revisions by 9 users not shown) |
| Line 1: |
Line 1: |
|
⚫ |
{{Short description|Monoclonal antibody}} |
|
{{Drugbox |
|
{{Drugbox |
|
⚫ |
| verifiedrevid = 464389745 |
|
| Verifiedfields = changed |
|
|
|
<!-- Monoclonal antibody data --> |
| ⚫ |
| verifiedrevid = 447741609 |
|
|
|
|
| ⚫ |
<!--Monoclonal antibody data--> |
|
|
| type = mab |
|
| type = mab |
|
| mab_type = |
|
| mab_type = |
|
| source = u |
|
| source = u |
|
| target = ] |
|
| target = ] |
|
⚫ |
<!-- Clinical data --> |
|
|
|
| ⚫ |
<!--Clinical data--> |
|
|
| tradename = |
|
| tradename = |
|
| pregnancy_AU = |
|
| pregnancy_AU = |
| Line 20: |
Line 18: |
|
| legal_status = |
|
| legal_status = |
|
| routes_of_administration = |
|
| routes_of_administration = |
|
⚫ |
<!-- Pharmacokinetic data --> |
|
|
|
| ⚫ |
<!--Pharmacokinetic data--> |
|
|
| bioavailability = |
|
| bioavailability = |
|
| protein_bound = |
|
| protein_bound = |
| Line 27: |
Line 24: |
|
| elimination_half-life = |
|
| elimination_half-life = |
|
| excretion = |
|
| excretion = |
|
⚫ |
<!-- Identifiers --> |
|
|
|
|
⚫ |
| CAS_number_Ref = {{cascite|correct|CAS}} |
| ⚫ |
<!--Identifiers--> |
|
|
⚫ |
| CAS_number = 138660-96-5 |
| ⚫ |
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
|
|
| UNII_Ref = {{fdacite|correct|FDA}} |
| ⚫ |
| ChemSpiderID = NA |
|
|
|
| UNII = HV6MT68KKF |
| ⚫ |
| CAS_number_Ref = {{cascite|correct|??}} |
|
|
⚫ |
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
| ⚫ |
| CAS_number = |
|
|
⚫ |
| ChemSpiderID = none |
|
| ATC_prefix = none |
|
| ATC_prefix = none |
|
| ATC_suffix = |
|
| ATC_suffix = |
|
|
| ChEMBL = 2108881 |
|
|
| KEGG = D05831 |
|
| PubChem = |
|
| PubChem = |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank = |
|
| DrugBank = |
|
⚫ |
<!-- Chemical data --> |
|
|
|
| ⚫ |
<!--Chemical data--> |
|
|
| chemical_formula = |
|
| chemical_formula = |
|
| molecular_weight = |
|
| molecular_weight = |
|
}} |
|
}} |
|
|
|
|
|
'''Sevirumab''' ('''MSL-109''') is a ] ] for the treatment of infections with ] in patients with ].<ref>{{cite journal|pmid=15498605|year=2004|last1=Borucki|first1=MJ|last2=Spritzler|last3=Asmuth|last4=Gnann|last5=Hirsch|last6=Nokta|last7=Aweeka|last8=Nadler|last9=Sattler|title=A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis|volume=64|issue=2|pages=103–11|doi=10.1016/j.antiviral.2004.06.012|journal=Antiviral research|first2=J|first3=DM|first4=J|first5=MS|first6=M|first7=F|first8=PI|first9=F}}</ref><ref> |
|
'''Sevirumab''' ('''MSL-109''') is a ] ] for the treatment of infections with ] in patients with ].<ref>{{cite journal | vauthors = Borucki MJ, Spritzler J, Asmuth DM, Gnann J, Hirsch MS, Nokta M, Aweeka F, Nadler PI, Sattler F, Alston B, Nevin TT, Owens S, Waterman K, Hubbard L, Caliendo A, Pollard RB | display-authors = 6 | title = A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis | journal = Antiviral Research | volume = 64 | issue = 2 | pages = 103–11 | date = November 2004 | pmid = 15498605 | doi = 10.1016/j.antiviral.2004.06.012 }}</ref><ref>{{ClinicalTrialsGov|NCT00000836|A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)}}</ref> |
|
|
|
|
|
==References== |
|
== References == |
|
{{reflist}} |
|
{{reflist}} |
|
|
|
|
| Line 52: |
Line 51: |
|
|
|
|
|
] |
|
] |
|
|
] |
|
|
|
|
|
|
|
{{antiinfective-drug-stub}} |
|
{{antiinfective-drug-stub}} |
|
{{monoclonal-antibody-stub}} |
|
{{monoclonal-antibody-stub}} |
